Measles, Mumps, Rubella Vaccine (Priorix™ GSK-MMR)

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Drugs

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00003495-200363190-00012
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• MEASLES (rubeola).

  2020cited by this paper
• 風疹ウイルス : 母児感染としての風疹感染(三日はしかrubella, german measles) (特集 OB/GYNウイルス感染症 : 外来診療マニュアル2003)

  2003cited by this paper
• Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine: a systematic review of current epidemiological evidence.

  2003cited by this paper
• Misled and confused? Telling the public about MMR vaccine safety

  2003cited by this paper
• The unfinished measles immunization agenda.

  2003cited by this paper
• Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case-crossover design.

  2003cited by this paper
• Prevalence of autism and parentally reported triggers in a north east London population

  2003cited by this paper
• Measles in Europe in 2001-2002.

  2003cited by this paper
• Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children

  2002cited by this paper
• Epidemiology of measles, mumps and rubella in Italy

  2002cited by this paper
• Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.

  2002cited by this paper
• United Kingdom divided as Scotland introduces free personal care for elderly people

  2002cited by this paper
• Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study

  2002cited by this paper
• The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997.

  2002cited by this paper
• Neurologic disorders after measles-mumps-rubella vaccination.

  2002cited by this paper
• Surveillance of Measles-Mumps-Rubella Vaccine-Associated Aseptic Meningitis in Germany

  2002cited by this paper
• Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age.

  2002cited by this paper
• Measles in Italy 2002: studies show correlation between vaccine coverage and incidence

  2002cited by this paper
• A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children.

  2002cited by this paper
• Consequences of delayed measles vaccination in Germany

  2002cited by this paper
• Erste Ergebnisse zum Impfstatus aus der Pilotphase des Kinder- und Jugendgesundheitssurveys

  2002cited by this paper
• Scottish expert group finds no link between MMR and autism

  2002cited by this paper
• Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain.

  2002cited by this paper
• A Population-Based Study of Measles, Mumps, and Rubella Vaccination and Autism

  2002cited by this paper
• MMR and autism: further evidence against a causal association.

  2001cited by this paper
• No evidence for a new variant of measles-mumps-rubella-induced autism.

  2001cited by this paper
• Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine Safety Datalink project.

  2001cited by this paper
• MMR immunization and autism.

  2001cited by this paper
• Neutralization Activity and Persistence of Antibodies Induced in Response to Vaccination with a Novel Mumps Strain, RIT 4385

  2001cited by this paper
• Immunogenicity and Reactogenicity of a New Measles, Mumps and Rubella Vaccine When Administered as a Second Dose at 12 y of Age

  2001cited by this paper
• Time trends in autism and in MMR immunization coverage in California.

  2001cited by this paper
• Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis

  2001cited by this paper
• Measles-mumps-rubella vaccine and autism: the rise (and fall?) of a hypothesis.

  2001cited by this paper
• Outbreak of aseptic meningitis associated with mass vaccination with a urabe-containing measles-mumps-rubella vaccine: implications for immunization programs.

  2000cited by this paper
• Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up.

  2000cited by this paper
• Measles, mumps, rubella vaccine: through a glass, darkly.

  2000cited by this paper
• Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines.

  2000cited by this paper
• Two outbreaks of mumps in children vaccinated with the Rubini strain in Spain indicate low vaccine efficacy.

  2000cited by this paper
• A national measles epidemic in Switzerland in 1997 : consequences for the elimination of measles by the year 2007.

  2000cited by this paper
• Autism and measles, mumps, and rubella vaccine.

  2000cited by this paper
• A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age.

  1999cited by this paper
• Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.

  1999cited by this paper
• Measles elimination: progress and challenges.

  1999cited by this paper
• Mumps and mumps vaccine: A global review

  1999cited by this paper
• Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association.

  1999cited by this paper
• Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children

  1998cited by this paper
• Measles, Mumps, and Rubella - Vaccine Use and Strategies for Elimination of Measles, Rubella, and Congenital Rubella Syndrome and Control of Mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Vol. 47/No. RR-8.

  1998cited by this paper
• Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children.

  1998cited by this paper
• No evidence for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14-year prospective study.

  1998cited by this paper
• Measles elimination in the Americas. Evolving strategies.

  1996cited by this paper
• Measles vaccine: a 27–year follow–up

  1994cited by this paper
• British National Formulary

  1994cited by this paper
• Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children.

  1993cited by this paper
• Evidence of persistent measles virus infection in Crohn's disease

  1993cited by this paper
• Rational Use of Measles, Mumps and Rubella (MMR) Vaccine

  1993cited by this paper
• Measles elimination.

  1990cited by this paper
• Rubella (German measles).

  1947cited by this paper

• The Strategies Used by Animal Viruses to Antagonize Host Antiviral Innate Immunity: New Clues for Developing Live Attenuated Vaccines (LAVs)

  2025cites this paper
• Comparative long-term follow-up study of persistence of immunity after JVC-001 measles, mumps, and rubella vaccination in Japanese children

  2025cites this paper
• Trend dynamics of mumps prevalence among children aged 1–9 years in Changzhou, 2005–2023: a joinpoint regression and age-period-cohort analysis

  2025cites this paper
• Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models

  2025cites this paper
• Understanding the influence of religious and safety concerns on childhood measles and pertussis vaccination: a study conducted in Aceh, Indonesia, 2022

  2025cites this paper
• The effect of mumps vaccine on the incidence of mumps in Hefei: An interrupted time-series analysis

  2025cites this paper
• Non-inferiority and vaccine titer-confirmation studies of MMR vaccine (JVC-001; measles AIK-C, mumps RIT4385, and rubella Takahashi strains) in healthy 1-year-old Japanese children.

  2025cites this paper
• A review of safety and immunogenicity of a novel measles, mumps, rubella (MMR) vaccine

  2024cites this paper
• Phase III, open-label, single-arm study of a new MMR vaccine (JVC-001); measles AIK-C, mumps RIT 4385, rubella Takahashi, as a second vaccine dose in healthy Japanese children aged 5-6 years.

  2024cites this paper
• Advancements in Vaccine Drug Delivery Systems: A Comprehensive Review

  2024cites this paper
• Are Measles-Mumps-Rubella (MMR) Antibodies Friends or Foes for Covid-19 Disease?

  2023cites this paper
• AN OVERVIEW OF SUBUNIT-BASED VACCINES FOR PULMONARY ADMINISTRATION

  2021cites this paper
• Immunization for Prevention of Ear, Nose, and Throat Infections in Children

  2021cites this paper
• Response to Vaccination against Mumps in Medical Students: Two Doses Are Needed

  2021cites this paper
• Forecasting the incidence of mumps in Chongqing based on a SARIMA model

  2021cites this paper
• Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis

  2020cites this paper
• Intralesional injection of measles, mumps, and rubella vaccine versus cryotherapy in treatment of warts: A randomized controlled trial

  2020cites this paper
• Current Status of Mumps Virus Infection: Epidemiology, Pathogenesis, and Vaccine

  2020influential citation
• Mumps Outbreaks in Vaccinated Populations—Is It Time to Re-assess the Clinical Efficacy of Vaccines?

  2020cites this paper
• Epidemiological changes in mumps infections between 1990 and 2017 in urban area of Shanghai, China

  2020cites this paper
• Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients

  2020cites this paper
• Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study

  2019cites this paper
• Measles, rubella, mumps and Toxoplasma gondii antibodies in saliva of vaccinated students of schools and universities in São Paulo City, Brazil

  2019cites this paper
• Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial

  2019cites this paper
• A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration

  2019cites this paper
• Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.

  2018cites this paper
• 40 – Mumps Vaccines

  2018cites this paper
• Multimodal safety assessment of measles‐mumps‐rubella vaccination after pediatric liver transplantation

  2018cites this paper
• Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study

  2018cites this paper
• Two-year antibody persistence in children vaccinated at 12–15 months with a measles-mumps-rubella virus vaccine without human serum albumin

  2017cites this paper
• An Overview of History, Evolution, and Manufacturing of Various Generations of Vaccines

  2017cites this paper
• Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.

  2017cites this paper
• Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.

  2017cites this paper
• Use of a current varicella vaccine as a live polyvalent vaccine vector.

  2016cites this paper
• Classification of Vaccines

  2015cites this paper
• Preservation of vaccine-induced long-term B cell memory and the effects of immunosuppressive treatment

  2015cites this paper
• 22 – Mumps vaccine

  2013cites this paper
• Epidemiology-driven neurodevelopmental animal models of schizophrenia.

  2010cites this paper